References
- Miserocchi E, Pontikaki I, Modorati G, et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory eye diseases. Autoimmun Rev. 2011;11:35–39
- Huerva V, Sanchez MC, Traveset A, et al. Rituximab for peripheral ulcerative keratitis with Wegener granulomatosis. Cornea. 2010;29:708–710
- Kroll JL, Beam C, Li S, et al. Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes. J Clin Virol. 2013;57:115–119
- Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–1312
- Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60:163–191
- Altamirano D, Rochat C, Claeys M, Herbort CP. Acute retinal necrosis: a result of immune dysfunction. Ophthalmologica. 1994;208:49–53
- Rochat C, Polla BS, Herbort CP. Immunological profiles in patients with acute retinal necrosis. Graefes Arch Clin Exp Ophthalmol. 1996;234:547–552